细胞结合补体生物标志物在系统性红斑狼疮中的应用：从实验台到病床边。
Cell-bound complement biomarkers for systemic lupus erythematosus: from benchtop to bedside.
机构信息
Lupus Center of Excellence, University of Pittsburgh School of Health Sciences, Pittsburgh, PA 15260, USA.
出版信息
Rheum Dis Clin North Am. 2010 Feb;36(1):161-72, x. doi: 10.1016/j.rdc.2009.12.003.
Abstract
Systemic lupus erythematosus is arguably the most clinically and serologically diverse autoimmune disease. This article highlights the biomarkers helpful in diagnosing this disease. The authors' own research is presented.
摘要
系统性红斑狼疮可以说是临床上和血清学上最多样化的自身免疫性疾病。本文重点介绍了有助于诊断这种疾病的生物标志物。本文呈现了作者自己的研究。
相似文献
1
Cell-bound complement biomarkers for systemic lupus erythematosus: from benchtop to bedside.
Rheum Dis Clin North Am. 2010 Feb;36(1):161-72, x. doi: 10.1016/j.rdc.2009.12.003.
2
Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus--a possible link to venous thrombosis?
Lupus. 2012 Nov;21(13):1423-32. doi: 10.1177/0961203312457210. Epub 2012 Aug 9.
3
Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity.
Arthritis Rheum. 1996 Jul;39(7):1178-88. doi: 10.1002/art.1780390716.
4
Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus.
Arthritis Rheum. 2010 Mar;62(3):837-44. doi: 10.1002/art.27267.
5
Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus.
Ann Rheum Dis. 1988 Nov;47(11):913-7. doi: 10.1136/ard.47.11.913.
6
Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus.
Clin Exp Rheumatol. 2014 Jan-Feb;32(1):48-53. Epub 2013 Aug 26.
7
Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus.
Clin Transl Sci. 2009 Aug;2(4):300-8. doi: 10.1111/j.1752-8062.2009.00135.x.
8
Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus.
Arthritis Rheumatol. 2020 Jan;72(1):78-88. doi: 10.1002/art.41093. Epub 2019 Nov 25.
9
C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings.
Am J Transplant. 2007 Mar;7(3):724. doi: 10.1111/j.1600-6143.2006.01642.x.
10
Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus.
Rheumatology (Oxford). 2020 Nov 1;59(11):3264-3274. doi: 10.1093/rheumatology/keaa092.
引用本文的文献
1
Cutting edge of genetically modified pigs targeting complement activation for xenotransplantation.
Front Immunol. 2024 Apr 4;15:1383936. doi: 10.3389/fimmu.2024.1383936. eCollection 2024.
2
Utility of the AVISE Connective Tissue Disease test in predicting lupus diagnosis and progression.
Lupus Sci Med. 2020 Mar 18;7(1):e000345. doi: 10.1136/lupus-2019-000345. eCollection 2020.
3
Potential Roles of Antiphospholipid Antibodies in Generating Platelet-C4d in Systemic Lupus Erythematosus.
Antibodies (Basel). 2017 Jul 2;6(3):9. doi: 10.3390/antib6030009.
4
Value of combined detection of anti-nuclear antibody, anti-double-stranded DNA antibody and C3, C4 complements in the clinical diagnosis of systemic lupus erythematosus.
Exp Ther Med. 2019 Feb;17(2):1390-1394. doi: 10.3892/etm.2018.7072. Epub 2018 Dec 7.
5
SLE and Serum Complement: Causative, Concomitant or Coincidental?
Open Rheumatol J. 2017 Sep 30;11:113-122. doi: 10.2174/1874312901711010113. eCollection 2017.
6
Cell-bound complement activation products in SLE.
Lupus Sci Med. 2017 Aug 21;4(1):e000236. doi: 10.1136/lupus-2017-000236. eCollection 2017.
7
Characterization and classification of lupus patients based on plasma thermograms.
PLoS One. 2017 Nov 17;12(11):e0186398. doi: 10.1371/journal.pone.0186398. eCollection 2017.
8
The Avise Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus.
Open Rheumatol J. 2016 Oct 31;10:71-80. doi: 10.2174/1874312901610010071. eCollection 2016.
9
Early Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune Diseases.
Front Immunol. 2016 Feb 15;7:36. doi: 10.3389/fimmu.2016.00036. eCollection 2016.
10
Biomarkers in systemic lupus erythematosus: challenges and prospects for the future.
Ther Adv Musculoskelet Dis. 2013 Aug;5(4):210-33. doi: 10.1177/1759720X13485503.
本文引用的文献
1
Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus.
Arthritis Rheum. 2010 Mar;62(3):837-44. doi: 10.1002/art.27267.
2
Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus.
Clin Transl Sci. 2009 Aug;2(4):300-8. doi: 10.1111/j.1752-8062.2009.00135.x.
3
Systemic lupus erythematosus.
N Engl J Med. 2008 Feb 28;358(9):929-39. doi: 10.1056/NEJMra071297.
4
Mechanisms of Disease: the complement system and the pathogenesis of systemic lupus erythematosus.
Nat Clin Pract Rheumatol. 2006 Jun;2(6):330-7. doi: 10.1038/ncprheum0191.
5
Platelet C4d is highly specific for systemic lupus erythematosus.
Arthritis Rheum. 2006 Feb;54(2):670-4. doi: 10.1002/art.21627.
6
Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus.
Arthritis Rheum. 2005 Oct;52(10):3087-99. doi: 10.1002/art.21305.
7
Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus.
Arthritis Rheum. 2004 Nov;50(11):3596-604. doi: 10.1002/art.20561.
8
Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients.
Semin Arthritis Rheum. 2004 Oct;34(2):501-37. doi: 10.1016/j.semarthrit.2004.07.002.
9
New advances in measurement of complement activation: lessons of systemic lupus erythematosus.
Curr Rheumatol Rep. 2004 Oct;6(5):375-81. doi: 10.1007/s11926-004-0012-5.
10
Complement as a source of biomarkers in systemic lupus erythematosus: past, present, and future.
Curr Rheumatol Rep. 2004 Apr;6(2):85-8. doi: 10.1007/s11926-004-0046-8.
Zotero 插件